Vergelijking
Afamelanotide vs. Cerebrolysin
Twee peptiden naast elkaar — identiteit, bewijsbasis, juridische status en bekende bijwerkingen.
Identiteit
Categorie
Onderzoek (overig)
Onderzoek (overig)
CAS-nr.
75921-69-6
96889-70-6
Molecuulmassa
1646.87 g/mol
geen gegevens
Halfwaardetijd
12 h
geen gegevens
Sequentie
Ac-Ser-Tyr-Ser-Nle-Glu-His-D-Phe-Arg-Trp-Gly-Lys-Pro-Val-NH2geen gegevens
Werkingsmechanisme
Afamelanotide
Afamelanotide is a synthetic analogue of α-melanocyte-stimulating hormone. It differs from native α-MSH by two substitutions — norleucine at position 4 and D-phenylalanine at position 7 — which make it metabolically more stable and more potent. As an agonist at the melanocortin-1 receptor (MC1R) on melanocytes, it activates adenylate cyclase, raises cAMP and increases tyrosinase activity via the transcription factor MITF. This shifts pigment synthesis toward eumelanin, which absorbs UV and visible light and has antioxidant properties — the presumed mechanism of photoprotection in EPP.
Cerebrolysin
Cerebrolysin is a mixture of low-molecular-weight peptides (predominantly below 10 kDa) and free amino acids obtained by enzymatic cleavage of lipid-free porcine brain proteins. The manufacturer and preclinical literature describe a neurotrophic and neuroprotective mode of action said to mimic endogenous neurotrophic factors; cell and animal models have reported effects on neuronal survival, synaptogenesis and anti-apoptotic signalling (including PI3K/Akt). Because it is a complex, incompletely characterised mixture, the precise mechanism in humans remains unclear.
Bewijsbasis
Hoogste bewijs
Humane RCT
Humane RCT
Studies
4
4
waarvan bij mensen
4
4
Geregistreerde effecten
4
4
Openstaande tegenstrijdigheden
1
1
Gedocumenteerde bijwerkingen
4
1
Juridische status
Volledige vermeldingen
Frequently asked questions
- What is the difference between Afamelanotide and Cerebrolysin?
- Afamelanotide is classified as "Onderzoek (overig)", while Cerebrolysin is classified as "Onderzoek (overig)". Afamelanotide: Afamelanotide (brand name Scenesse) is a synthetic 13-amino-acid analogue of α-melanocyte-stimulating hormone (α-MSH) and a melanocortin-1 receptor agonist. Unlike most peptides covered here, it is a regularly approved medicine: EMA approval in 2014/2015, FDA approval in 2019, in each case as a subcutaneous implant for the prevention of phototoxicity in adults with erythropoietic protoporphyria (EPP). It promotes eumelanin formation in the skin. Cerebrolysin: Cerebrolysin (FPF-1070) is not a single peptide but a porcine-brain-derived preparation of low-molecular-weight peptides and free amino acids, produced by standardised enzymatic proteolysis. It is approved in several countries (including Austria, Russia and parts of Asia) for stroke, dementia and traumatic brain injury, but is not FDA-approved in the United States and not centrally approved by the EMA. Its efficacy is contested: Cochrane systematic reviews found no convincing benefit and flagged possible harm signals. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.
- Which peptide is better supported by science, Afamelanotide or Cerebrolysin?
- The highest available evidence level is "Humane RCT" for Afamelanotide and "Humane RCT" for Cerebrolysin. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.
- What is the legal status of Afamelanotide and Cerebrolysin in Germany and the United States?
- Duitsland: Afamelanotide — Op recept, Cerebrolysin — Onduidelijk. Verenigde Staten: Afamelanotide — Op recept, Cerebrolysin — Niet goedgekeurd. These are factual summaries with source and review date on the individual pages.